PDCD1 and neoplasm: Our results showed that not only the erythrocytes part of the system could improve the tumor accumulation of siPD‐L1, but also the released FEGCG/Zn and siPD‐L1 could alleviate T cells exhaustion by blocking PD‐1/PD‐L1 engagement, resulting in the enhanced efficacy of anti‐PD‐L1 immunotherapy (Figure 1b‐c).